Comparison

Tolterodine European Partner

Item no. HY-A0024-5mg
Manufacturer MedChem Express
CASRN 124937-51-5
Amount 5 mg
Quantity options 100 mg 10mM/1mL 10 mg 25 mg 50 mg 5 mg
Category
Type Inhibitors
Specific against other
Purity 98.63
Formula C22H31NO
Citations [1]Nilvebrant L. Tolterodine and its active 5-hydroxymethyl metabolite: pure muscarinic receptor antagonists. Pharmacol Toxicol. 2002 May;90(5):260-7.
[2]Andersson SH, et al. Biotransformation of tolterodine, a new muscarinic receptor antagonist, in mice, rats, and dogs. Drug Metab Dispos. 1998 Jun;26(6):528-35.
[3]Cappon GD, et al. Tolterodine does not affect memory assessed by passive-avoidance response test in mice. Eur J Pharmacol. 2008 Jan 28;579(1-3):225-8.
Smiles CC(C)N(C(C)C)CC[C@H](C1=CC=CC=C1)C2=C(O)C=CC(C)=C2
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Alias (R)-(+)-Tolterodine; (+)-Tolterodine; (R)-Tolterodine; PNU-200583
Shipping Condition Cool pack
Available
Manufacturer - Type
Reference compound
Manufacturer - Applications
Neuroscience-Neuromodulation
Manufacturer - Targets
mAChR
Shipping Temperature
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Molecular Weight
325.49
Product Description
Tolterodine(PNU-200583) is a potent muscarinic receptor antagonists that show selectivity for the urinary bladder over salivary glands in vivo.
IC50 Value:
Target: mAChR
in vitro: Carbachol-induced contractions of isolated guinea pig bladder were effectively inhibited by tolterodine (IC50 14 nM) and 5-HM (IC50 5.7 nM). The IC50 values were in the microM range and the antimuscarinic potency of tolterodine was 27, 200 and 370-485 times higher, respectively, than its potency in blocking histamine receptors, alpha-adrenoceptors and calcium channels. The active metabolite, 5-HM, was >900 times less potent at these sites than at bladder muscarinic receptors [1].
in vivo: Tolterodine was extensively metabolized in vivo [2]. In the passive-avoidance test, tolterodine at 1 or 3 mg/kg had no effect on memory; the latency to cross and percentage of animals crossing were comparable to controls. In contrast, scopolamine induced a memory deficit; the latency to cross was decreased, and the number of animals crossing was increased [3].
Manufacturer - Research Area
Neurological Disease; Cancer
Solubility
DMSO : 100 mg/mL (ultrasonic)|Ethanol : 120 mg/mL (ultrasonic)
Manufacturer - Pathway
GPCR/G Protein; Neuronal Signaling
Clinical information
Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 5 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close